Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: GlobeNewswire
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure (“oSBP”)97% of patients experienced an immediate blood pressure reduction of 5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboration with Medtronic (NYSE: MDT), targets a similar patient population as MODERATO II using a similar approach to blood pressure assessment and AVIM Therapy activation NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed (OBIO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (e+)".MarketBeat
- Orchestra BioMed (OBIO) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Orchestra BioMed (OBIO) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "strong MarketBeat
- Orchestra BioMed (OBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]Yahoo! Finance
OBIO
Sec Filings
- 3/27/26 - Form 4
- 3/27/26 - Form 4
- 3/27/26 - Form 4
- OBIO's page on the SEC website